Handa Oncology receives FDA final approval for OMCAZIO cabozantinib
FDA granted final approval for OMCAZIO (cabozantinib) capsules, including administration without regard to food and removal of strict fasting requirements for cabozantinib patients.
OMCAZIO has been approved for administration without regard to food, removing the strict fasting requirements for cabozantinib patients. SAN JOSE, CA AND TAIPEI, TW / / September 11, 2026 / Handa Pharmaceuticals, Inc. S. Food and Drug Admini…